Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population

被引：0
|
作者：
T.-C. Lin
C.-Y. Yang
Y.-H. Kao Yang
S.-J. Lin
机构：
[1] National Cheng Kung University,Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine
[2] National Cheng Kung University,Department of Orthopedics, College of Medicine
[3] National Cheng Kung University Hospital,Department of Orthopedics
[4] National Cheng Kung University,Health Outcome Research Center
[5] University of Illinois at Chicago,Department of Pharmacy Administration
来源：
Osteoporosis International | 2014年 / 25卷
关键词：
Alendronate; Osteonecrosis of the jaw; Osteoporosis; Pharmacoepidemiology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1503 / 1511
页数：8
相关论文
共 50 条
  • [21] Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan
    Ishimaru, Miho
    Ono, Sachiko
    Morita, Kojiro
    Matsui, Hiroki
    Hagiwara, Yasuhiro
    Yasunaga, Hideo
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2022, 80 (04) : 714 - 727
  • [22] Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink
    Rebecca Persson
    Katrina Wilcox Hagberg
    Emma Pranschke
    Catherine Vasilakis-Scaramozza
    Susan Jick
    Osteoporosis International, 2025, 36 (1) : 47 - 60
  • [23] Higher Risk of Osteonecrosis of the Jaw under Denosumab compared to Bisphosphonates in Patients with Osteoporosis
    Everts-Graber, Judith
    Lehmann, Daniel
    Reichenbach, Stephan
    Gahl, Brigitta
    Schaller, Benoit
    Burkhard, John Patrik
    Hauselmann, HansJorg
    Ziswiler, Hans-Ruedi
    Studer, Ueli
    Lehmann, Thomas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 68 - 68
  • [24] OSTEONECROSIS OF THE JAW IN A PATIENT WITH OSTEOPOROSIS TREATED WITH DENOSUMAB
    Mazurenko, S. O.
    Dunaevskaya, N. N.
    Tsoi, N. V.
    Strigina, N. G.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S83 - S84
  • [25] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [26] Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis
    Gadgaard, N. R.
    Olesen, T. B.
    Svane, H. M. L.
    Heide-Jorgensen, U.
    Norholt, S. E.
    Ehrenstein, V.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2022, 51 (11) : 1424 - 1430
  • [27] Diabetes and the risk of osteonecrosis of the jaw
    Favus, Murray J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03): : 817 - 818
  • [28] Aflibercept: risk of osteonecrosis of the jaw
    Reactions Weekly, 2016, 1595 (1) : 1 - 1
  • [29] Bisphosphonates and the risk of osteonecrosis of the jaw
    Reactions Weekly, 2009, 1278 (1) : 3 - 3
  • [30] ATTITUDES AND KNOWLEDGE OF COLOMBIAN DENTISTS ABOUT THE RISK OF OSTEONECROSIS OF THE JAW AMONG PATIENTS RECEIVING TREATMENT FOR OSTEOPOROSIS WITH BISPHOSPHONATES OR DENOSUMAB
    Avila, Vaneza
    Fernandez, Daniel
    Moreno, Isabel
    Ballen, Diego
    Porras, Juliana
    Gutierrez, Juan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 123 - 124
12345